Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen
AssigneeUniversity of Kansas Medical Center
InventorsBilly G. Hudson, Michael P. Sarras, Jr.
Life of this patent
Estimating the term…
Abstract
The instant invention provides methods and kits for inhibiting angiogenesis, tumor growth and metastasis, and endothelial cell interactions with the extracellular matrix, involving contacting the tumor or animal tissue with at least one isolated type IV collagen NC1 a chain monomer. In a specific embodiment of the invention, the isolated domain of type IV collagen comprises the NC1 (α1), (α2), (α3), or (α6) chain monomer, or protein constructs having substantially the same structure as the NC1 (α1), (α2), (α3), or (α6) chain monomer.
Claims2
A method for treating an angiogenesis-mediated disease or condition in a mammal, comprising administering to a mammal with an angiogenesis-mediated disease or condition an amount effective to inhibit angiogenesis of a polypeptide composition comprising the isolated NC1 α chain monomer of type IV collagen α2.
Dependencies are inferred from the claim text.